Zelnecirnon
Product Specifications
UNSPSC Description
Zelnecirnon (RPT193) is an orally active inhibitor of CCR4, blocks the recruitment of Th2 inflammatory immune cells into inflamed tissues. Zelnecirnon can be used for allergic inflammation in atopic dermatitis, asthma, and other diseases research[1].
Target Antigen
CCR
Type
Reference compound
Related Pathways
GPCR/G Protein;Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/zelnecirnon.html
Solubility
DMSO : 100 mg/mL (ultrasonic)|Methanol : 250 mg/mL (ultrasonic)
Smiles
C[C@H](C1=C(C=C(C=C1)Cl)Cl)NC2=NC(N3CC([C@@H]4CN([C@H]5C[C@@](C)(C5)C(O)=O)CCC4)C3)=NC(C)=C2Cl
Molecular Weight
566.95
References & Citations
[1]Bissonnette R, et al. RPT193, an oral CCR4 inhibitor: Efficacy results from a randomized, placebo-controlled Phase 1b monotherapy trial in patients with moderate-to-severe atopic dermatitis[C]//EXPERIMENTAL DERMATOLOGY. 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY, 2021, 30: 40-41.|[2]Cheng L, et al. Development and first-in-human characterization of a potent oral CCR4 antagonist for the treatment of atopic dermatitis[C]//Journal of Investigative Dermatology. STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA: ELSEVIER SCIENCE INC, 2020, 140(7): S77-S77.
Shipping Conditions
Blue Ice
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-148074/Zelnecirnon-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-148074/Zelnecirnon-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
2366152-15-8
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6291002-01 0.2 mL
Dcc, CT (Dcc, Netrin receptor DCC, Tumor suppressor protein DCC) (AP)
Ask
View Details 
MBS6291002-02 5x 0.2 mL
Dcc, CT (Dcc, Netrin receptor DCC, Tumor suppressor protein DCC) (AP)
Ask
View Details